 |
|
|
| |
Longer treatment duration of monthly VIR-2218 results in deeper and more sustained reductions in hepatitis B surface antigen in participants with chronic hepatitis B infection
|
| |
| |
European Association for the Study of the Liver (EASL): International Liver Conference 22-26 June 2002; London, England
oral presentation
Young-Suk Lim,1 Man-Fung Yuen,2 Daniel Cloutier,3 Vaidehi Thanawala,3 Ling Shen,3 Sneha V. Gupta,3 Andre Arizpe,3 Andrea L. Cathcart,3 Carey Hwang,3 Edward Gane4
1Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; 2Queen Mary Hospital, The University of Hong Kong, Hong Kong, China; 3Vir Biotechnology, Inc., San Francisco, CA; 4Faculty of Medicine, University of Auckland, Auckland, New Zealand
|
| |
|
|
|
|
|
